Changes in breast cancer transcriptional profiles after treatment with the aromatase inhibitor, letrozole

Breast Research Group, University of Edinburgh, Edinburgh, UK.
Pharmacogenetics and Genomics (Impact Factor: 3.45). 10/2007; 17(10):813-26. DOI: 10.1097/FPC.0b013e32820b853a
Source: PubMed

ABSTRACT The aim of the study was to identify changes in tumour expression profiling associated with short-term therapy of breast cancer patients with letrozole.
Microarray analysis was performed on RNA extracted from paired tumour core biopsies taken before and after 14 days of treatment with letrozole (2.5 mg/daily) in 58 patients. Changes in expression profile were identified by three different approaches on the basis of frequency of changes, magnitude of changes and significance analysis of microarray.
No single gene was consistently changed by therapy in all cases. Fifty-two genes, however, were downregulated and 36 upregulated in at least 45 of the 58 cases. In terms of quantitative change, 46 genes showed at least a median 1.5-fold change in expression. Significance analysis of microarray identified 62 genes that were significantly changed by therapy (P<0.0001, 56 downregulated and six upregulated). All three approaches showed that greater numbers of genes were downregulated rather than upregulated. Merging data produced a total of 143 genes, which were subject to gene ontology and cluster analysis. The ontology of the 91 downregulated genes showed that they were functionally associated with cell cycle progression, particularly mitosis. In contrast, upregulated genes were associated with organ development, connective tissue extracellular matrix regulation and inflammatory response. Cluster analysis segregated the patients into four groups differing in patterns of gene expression.
Genes have been identified which either change markedly or consistently in breast cancer after 14 days treatment with letrozole. These are new important data in understanding letrozole's molecular mechanism of action in breast cancers.

Download full-text


Available from: Alexey A Larionov, Aug 14, 2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: The use of neoadjuvant therapy is well established in the treatment of the breast cancer, and neoadjuvant endocrine therapy is emerging as a safe and an effective alternative to chemotherapy in selected patients with a hormone receptor–positive locally advanced breast cancer without compromising survival rates. Neoadjuvant endocrine therapy increases the rate of breast conservative surgery in women initially requiring mastectomy, and the latest generation of endocrine therapy, the aromatase inhibitors, has been proved to be superior to tamoxifen. Biomarkers such as Ki67, estrogen receptor, and the PEPI index can be used to select and monitor patients if neoadjuvant endocrine therapy is considered. Biomarkers can give predictive information in weeks, and alternative treatment can be considered before or after surgical resection. The benefits of the neoadjuvant approach are not only tumor size reduction to improve surgical approach, but also to better understand the impact of the treatment on the tumor and treatment resistance due to tumor heterogeneity.
    Current Breast Cancer Reports 06/2012; 4(2). DOI:10.1007/s12609-012-0077-5
  • Source
    Breast Cancer Research 12/2007; 9(Suppl 2). DOI:10.1186/bcr1815 · 5.33 Impact Factor
  • Breast Cancer Online 01/2008; 11(01). DOI:10.1017/S1470903107006657
Show more